Headquartered in New Haven, CT,Achillion applies expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving the lives of patients. More...
Hepatitis C is a worldwide epidemic affecting more than 150 million individuals. Click to learn more about this disease.
JMP Securities Life Sciences Conference
Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen
Achillion Reports First Quarter 2015 Financial Results
On May 19, 2015, Achillion entered into a worldwide collaboration with Janssen to combat hepatitis C.